← Back to all trials
Recruiting
NCT06658353
Phase III Clinical Study of VC004 in Patients With Localized Advanced/ Metastatic Solid Tumors
Conditions: Locally Advanced Solid Tumor
Sex: All
Ages: 12 Years – N/A
Healthy volunteers: No
Phase: PHASE3
Enrollment: 54
Sponsor: Jiangsu vcare pharmaceutical technology co., LTD
Location: Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College Beijing Beijing Municipality
Summary
This Study is a single arm, open label, multicenter phase III clinical trial to evaluate the safety and efficacy of VC004 in patients with locally advanced/metastatic solid tumors.
Eligibility Criteria
Inclusion Criteria:
* All subjects or legal representatives are willing and able to sign ICF approved by the ethics committee before starting any screening procedures；
* Male or female, age ≥12 years old;
Exclusion Criteria:
* Patients have undergone major surgery within 4 weeks prior to the first dose or are expected to undergo major surgery during the trial (excluding vascular access establishment procedures, biopsy procedures);
* Adverse reactions caused by previous treatment have not recovered to ≤1 grade (evaluated by the investigator);
* Patients had been treated with a strong CYP3A inhibitor or inducer within 7 days prior to the first administration of the study drug.
Source: ClinicalTrials.gov (NCT06658353). StuddyBuddy aggregates publicly available trial information.
